Nifty
:
26033.75
Sensex
:
85265.32
47.75 (0.18%)
158.51 (0.19%)
Nifty
Sensex
:
:
26033.75
85265.32
47.75 (0.18%)
158.51 (0.19%)

Zydus Lifesciences Ltd.

Pharmaceuticals & Drugs - Global

Rating :
75/99

BSE: 532321 | NSE: ZYDUSLIFE

NSE BSE
935.75
04-Dec-2025
  • Open
  • High
  • Low
  • Previous Close
  •  938
  •  944.15
  •  932.55
  •  934.95
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  874529
  •  819263625.5
  •  1059.05
  •  795

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 94,103.00
  • 19.13
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,00,914.40
  • 1.18%
  • 3.72

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.99%
  • 0.56%
  • 5.49%
  • FII
  • DII
  • Others
  • 7.34%
  • 10.62%
  • 1.00%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.44
  • 10.04
  • 10.48

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.46
  • 15.28
  • 14.05

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.98
  • 15.71
  • 33.68

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.79
  • 23.15
  • 23.44

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.70
  • 3.74
  • 4.03

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.48
  • 14.98
  • 14.99

Earnings Forecasts:

(Updated: 29-11-2025)
Description
2024
2025
2026
2027
Adj EPS
44.97
44.95
41.49
46.14
P/E Ratio
20.81
20.82
22.55
20.28
Revenue
22573.8
25602.3
27079.8
29331.9
EBITDA
6895.1
6897.77
6583.08
7053.41
Net Income
4525.5
4588.12
4209.85
4601.05
ROA
13.61
11.77
9.87
9.99
P/B Ratio
3.93
3.39
3.02
2.68
ROE
20.67
17.39
14.15
13.73
FCFF
5157.1
594.91
3767.84
3845.31
FCFF Yield
5.58
0.64
4.08
4.16
Net Debt
-4594.7
-2996.16
-4749.84
-3605
BVPS
238.05
275.97
310.21
349.16

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Net Sales
6,123.20
5,237.00
16.92%
6,573.70
6,207.50
5.90%
6,527.90
5,533.80
17.96%
5,269.10
4,505.20
16.96%
Expenses
4,521.50
3,821.00
18.33%
4,542.30
4,123.50
10.16%
4,402.40
3,908.60
12.63%
3,881.50
3,402.80
14.07%
EBITDA
1,601.70
1,416.00
13.11%
2,031.40
2,084.00
-2.52%
2,125.50
1,625.20
30.78%
1,387.60
1,102.40
25.87%
EBIDTM
26.16%
27.04%
30.90%
33.57%
32.56%
29.37%
26.33%
24.47%
Other Income
523.10
113.60
360.48%
212.00
63.20
235.44%
80.60
161.70
-50.15%
57.50
37.70
52.52%
Interest
101.30
25.10
303.59%
84.70
32.20
163.04%
76.60
34.60
121.39%
32.00
19.80
61.62%
Depreciation
301.90
233.60
29.24%
238.10
215.30
10.59%
237.90
205.30
15.88%
229.00
194.80
17.56%
PBT
1,687.40
1,270.90
32.77%
1,920.60
1,899.70
1.10%
1,672.00
1,547.00
8.08%
1,184.10
925.50
27.94%
Tax
454.00
373.10
21.68%
434.00
436.10
-0.48%
423.20
321.20
31.76%
179.50
213.80
-16.04%
PAT
1,233.40
897.80
37.38%
1,486.60
1,463.60
1.57%
1,248.80
1,225.80
1.88%
1,004.60
711.70
41.15%
PATM
20.14%
17.14%
22.61%
23.58%
19.13%
22.15%
19.07%
15.80%
EPS
12.51
9.06
38.08%
14.58
14.11
3.33%
11.64
11.75
-0.94%
10.17
7.80
30.38%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
24,493.90
23,241.50
19,547.40
17,237.40
15,109.90
14,403.50
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
Net Sales Growth
14.01%
18.90%
13.40%
14.08%
4.90%
1.06%
8.26%
10.13%
27.49%
-0.53%
 
Cost Of Goods Sold
6,760.50
5,345.40
5,260.10
5,335.70
4,757.00
4,094.20
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
Gross Profit
17,733.40
17,896.10
14,287.30
11,901.70
10,352.90
10,309.30
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
GP Margin
72.40%
77.00%
73.09%
69.05%
68.52%
71.57%
70.23%
68.54%
69.41%
67.31%
71.64%
Total Expenditure
17,347.70
16,348.00
14,248.40
13,665.50
11,935.20
11,018.20
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
Power & Fuel Cost
-
358.20
366.30
343.50
299.30
231.60
252.90
231.60
211.40
174.50
155.40
% Of Sales
-
1.54%
1.87%
1.99%
1.98%
1.61%
1.77%
1.76%
1.77%
1.86%
1.65%
Employee Cost
-
3,289.70
2,789.00
2,456.40
2,177.70
2,069.50
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
% Of Sales
-
14.15%
14.27%
14.25%
14.41%
14.37%
15.22%
14.46%
13.76%
15.84%
11.87%
Manufacturing Exp.
-
3,445.60
2,758.10
2,639.80
2,272.30
2,271.40
2,230.00
1,923.20
1,680.40
955.30
1,397.60
% Of Sales
-
14.83%
14.11%
15.31%
15.04%
15.77%
15.65%
14.61%
14.06%
10.19%
14.83%
General & Admin Exp.
-
933.50
625.00
620.30
506.70
444.00
582.60
583.40
398.70
466.00
356.40
% Of Sales
-
4.02%
3.20%
3.60%
3.35%
3.08%
4.09%
4.43%
3.34%
4.97%
3.78%
Selling & Distn. Exp.
-
2,362.20
1,800.10
1,674.60
1,373.30
1,358.60
1,468.40
1,033.30
1,129.40
826.40
979.60
% Of Sales
-
10.16%
9.21%
9.71%
9.09%
9.43%
10.30%
7.85%
9.45%
8.81%
10.39%
Miscellaneous Exp.
-
613.40
649.80
595.20
548.90
548.90
525.90
371.20
404.40
502.60
979.60
% Of Sales
-
2.64%
3.32%
3.45%
3.63%
3.81%
3.69%
2.82%
3.38%
5.36%
4.41%
EBITDA
7,146.20
6,893.50
5,299.00
3,571.90
3,174.70
3,385.30
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
EBITDA Margin
29.18%
29.66%
27.11%
20.72%
21.01%
23.50%
19.51%
22.62%
23.66%
20.28%
24.71%
Other Income
873.20
459.60
369.40
474.60
390.70
47.40
117.10
208.50
133.00
147.10
116.60
Interest
294.60
191.00
81.20
129.90
127.00
158.80
341.80
195.80
110.80
63.10
52.80
Depreciation
1,006.90
915.80
764.10
722.70
713.00
669.60
696.50
598.60
538.80
373.30
292.10
PBT
6,464.10
6,246.30
4,823.10
3,193.90
2,725.40
2,604.30
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
Tax
1,490.70
1,411.90
977.50
587.80
511.70
193.60
319.80
530.30
564.40
128.90
177.40
Tax Rate
23.06%
23.43%
20.33%
22.70%
18.03%
8.07%
21.39%
22.26%
24.41%
8.00%
8.45%
PAT
4,973.40
4,467.70
3,718.10
1,870.30
2,195.40
2,154.20
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
PAT before Minority Interest
4,863.70
4,614.80
3,831.40
2,001.90
2,326.40
2,205.60
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
Minority Interest
-109.70
-147.10
-113.30
-131.60
-131.00
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
PAT Margin
20.30%
19.22%
19.02%
10.85%
14.53%
14.96%
8.05%
13.69%
14.33%
15.51%
20.06%
PAT Growth
15.69%
20.16%
98.80%
-14.81%
1.91%
87.68%
-36.30%
5.19%
17.82%
-23.11%
 
EPS
49.43
44.40
36.95
18.59
21.82
21.41
11.41
17.91
17.02
14.45
18.79

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
23,953.10
19,829.50
17,515.80
16,999.60
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
Share Capital
100.60
100.60
101.20
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
23,852.50
19,728.90
17,414.60
16,897.20
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
Non-Current Liabilities
-542.10
193.10
-725.00
-193.60
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
Secured Loans
0.00
0.00
0.00
0.00
0.00
1,953.60
2,332.80
200.60
319.60
393.80
Unsecured Loans
0.00
0.00
0.00
362.10
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
Long Term Provisions
383.90
309.70
271.80
325.00
309.50
235.20
184.10
155.90
151.20
120.70
Current Liabilities
9,041.60
5,339.70
5,526.70
7,826.80
7,861.30
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
Trade Payables
2,305.80
2,126.70
2,125.00
2,137.80
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
Other Current Liabilities
2,499.20
1,677.60
1,798.50
1,967.50
2,166.20
2,126.30
2,033.60
1,484.90
1,212.10
860.70
Short Term Borrowings
3,169.50
768.60
1,081.00
3,314.10
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
Short Term Provisions
1,067.10
766.80
522.20
407.40
418.30
272.30
189.40
152.20
68.90
81.30
Total Liabilities
34,857.90
27,634.40
24,490.00
26,687.00
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
Net Block
13,133.70
12,368.50
11,520.90
12,188.50
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
Gross Block
21,699.80
19,919.80
18,343.80
17,650.90
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
Accumulated Depreciation
8,566.10
7,551.30
6,822.90
5,462.40
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
Non Current Assets
17,811.80
16,135.20
14,477.60
14,438.20
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
Capital Work in Progress
2,691.90
2,423.30
1,200.70
725.90
783.20
741.50
837.20
1,527.20
1,543.30
950.80
Non Current Investment
1,556.70
968.00
927.30
934.80
631.20
552.20
443.60
470.90
385.70
217.10
Long Term Loans & Adv.
400.10
344.50
358.70
369.30
323.30
332.00
410.40
300.00
384.70
661.20
Other Non Current Assets
29.40
30.90
470.00
219.70
223.80
262.10
159.80
130.30
234.10
174.70
Current Assets
17,046.10
11,419.80
10,008.20
12,095.20
8,716.00
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
Current Investments
4,851.10
252.50
619.30
2,353.20
198.90
212.80
229.90
274.80
49.10
199.10
Inventories
3,944.00
3,441.90
3,413.30
3,719.40
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
Sundry Debtors
4,024.70
5,220.20
4,416.80
3,340.30
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
Cash & Bank
2,956.80
1,105.10
573.10
1,106.90
888.30
964.90
548.90
1,314.90
1,543.50
638.70
Other Current Assets
1,269.50
664.20
274.00
229.90
1,265.30
1,085.50
1,080.50
1,048.40
348.50
358.90
Short Term Loans & Adv.
717.30
735.90
711.70
1,345.50
741.40
643.90
584.50
527.70
268.50
234.80
Net Current Assets
8,004.50
6,080.10
4,481.50
4,268.40
854.70
446.00
1,155.60
2,146.70
716.50
819.40
Total Assets
34,857.90
27,555.00
24,485.80
26,533.40
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
6,776.70
3,196.30
2,688.80
2,104.50
3,293.90
2,931.50
1,281.90
919.30
1,311.70
1,893.50
PBT
6,026.70
4,838.10
2,582.70
5,232.30
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
Adjustment
1,020.40
546.70
933.90
-2,117.20
1,163.00
1,474.40
539.10
624.30
333.70
249.80
Changes in Working Capital
1,531.50
-902.70
-235.80
-336.00
191.10
263.80
-971.70
-1,383.90
-411.20
271.70
Cash after chg. in Working capital
8,578.60
4,482.10
3,280.80
2,779.10
3,638.90
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,801.90
-1,285.80
-592.00
-674.60
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.40
7.80
-30.80
14.90
-80.70
Cash From Investing Activity
-8,372.30
-1,475.20
1,535.00
-1,000.30
-724.60
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
Net Fixed Assets
-776.80
-572.20
-669.30
-490.20
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
Net Investments
-4,208.50
-2,403.70
238.70
1,352.60
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
Others
-3,387.00
1,500.70
1,965.60
-1,862.70
-195.30
1,486.20
-2,009.30
-679.10
-708.30
-223.60
Cash from Financing Activity
2,014.20
-1,778.80
-4,400.40
-868.30
-2,547.70
-1,528.20
1,884.60
51.50
2,315.80
-934.80
Net Cash Inflow / Outflow
418.60
-57.70
-176.60
235.90
21.60
391.00
-1,072.20
-2.90
755.60
95.20
Opening Cash & Equivalents
413.00
487.80
657.80
888.30
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
Closing Cash & Equivalent
826.80
413.00
487.80
1,106.90
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
238.10
197.11
173.08
166.01
126.88
101.33
101.43
85.40
67.97
55.66
ROA
14.77%
14.70%
7.82%
9.40%
9.66%
5.18%
9.34%
11.11%
12.18%
20.14%
ROE
21.08%
20.52%
11.60%
15.51%
18.88%
11.32%
19.36%
22.26%
23.43%
38.62%
ROCE
26.06%
24.90%
13.64%
15.30%
14.23%
10.02%
15.89%
18.41%
16.50%
28.60%
Fixed Asset Turnover
2.20
1.98
1.88
1.69
1.69
0.88
1.05
1.38
1.38
1.76
Receivable days
36.93
46.37
41.75
39.94
42.92
97.49
99.21
83.37
76.72
63.29
Inventory Days
29.51
32.98
38.39
42.95
38.08
70.13
70.33
63.69
59.88
54.52
Payable days
151.33
147.51
145.80
166.64
189.45
64.85
68.81
68.11
74.18
65.30
Cash Conversion Cycle
-84.89
-68.16
-65.67
-83.76
-108.45
102.77
100.73
78.94
62.42
52.51
Total Debt/Equity
0.13
0.04
0.07
0.25
0.35
0.77
0.76
0.62
0.75
0.43
Interest Cover
32.55
60.22
20.94
23.35
16.11
5.38
13.17
21.87
26.55
40.75

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Zydus Lifesciences gets EIR from USFDA for Jarod injectable facility
    4th Dec 2025, 15:59 PM

    This inspection was conducted following the warning letter issued on August 29, 2024 by the USFDA

    Read More
  • Zydus Lifesciences gets USFDA’s tentative nod for Empagliflozin and Linagliptin Tablets
    28th Nov 2025, 10:12 AM

    Empagliflozin and Linagliptin Tablets had annual sales of $215.8 million in the United States

    Read More
  • Zydus Lifesciences inks exclusive licensing and commercialization pact with RK Pharma Inc
    26th Nov 2025, 14:59 PM

    Under this pact, RK Pharma will manufacture and supply the finished product, while the company will be responsible for the NDA submission and commercialization of the product in the US

    Read More
  • Zydus Lifesciences gets final nod for Verapamil Hydrochloride Extended Release Tablets
    26th Nov 2025, 10:13 AM

    Verapamil Hydrochloride Extended-Release Tablets will be produced at Zydus Lifesciences, Baddi, Himachal Pradesh

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Leuprolide Acetate injection
    14th Nov 2025, 15:42 PM

    Leuprolide Acetate injection had annual sales of $69 million in the United States

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Diroximel Fumarate delayed-release capsules
    14th Nov 2025, 12:21 PM

    Diroximel fumarate delayed-release capsules will be produced at Zydus Lifesciences, SEZ

    Read More
  • Zydus Lifesciences gets USFDA’s tentative approval for Diroximel Fumarate delayed-release capsules
    13th Nov 2025, 16:44 PM

    Diroximel fumarate delayed-release capsules will be produced at Zydus Lifesciences, SEZ

    Read More
  • Zydus Lifesciences’ Amplitude secures CE mark for robotic surgical system
    13th Nov 2025, 15:51 PM

    Amplitude Surgical (Amplitude) is a wholly owned subsidiary of Zydus MedTech France SAS, a wholly owned subsidiary of the company

    Read More
  • Zydus Lifesciences gets NMPA’s approval for Venlafaxine ER capsules
    11th Nov 2025, 12:50 PM

    Venlafaxine ER Capsules will be produced at the company’s manufacturing facility at Moraiya, Ahmedabad

    Read More
  • Zydus Lifesciences gets USFDA’s approval for Olaparib Tablets
    8th Nov 2025, 11:57 AM

    Olaparib tablets had annual sales of $1,379.4 million in the United States

    Read More
  • Zydus Lifesciences’ consolidated net profit surges 38% in Q2
    7th Nov 2025, 14:50 PM

    The consolidated total income of the company increased by 17.47% at Rs 6,232.20 crore for Q2FY26

    Read More
  • Zydus Lifesciences - Quarterly Results
    7th Nov 2025, 00:00 AM

    Read More
  • Zydus Lifesciences gets Orphan Drug Designation from USFDA for Desidustat
    6th Nov 2025, 14:42 PM

    Desidustat is a HIF-PHI and has the potential to increase haemoglobin and red blood cell counts

    Read More
  • Zydus Lifesciences gets EIR report with Nill observations from USFDA
    5th Nov 2025, 16:58 PM

    The company has received the establishment inspection report for an inspection at the group’s manufacturing plant located SEZ - II, Ahmedabad

    Read More
  • Zydus Lifesciences gets USFDA’s tentative approval for Budesonide capsules
    5th Nov 2025, 15:30 PM

    Budesonide capsules will be produced at is Zydus Pharmaceuticals

    Read More
  • Zydus Lifesciences gets EIR for Baddi facility from USFDA
    30th Oct 2025, 09:48 AM

    The EIR has classified the facility as Voluntary Action Indicated

    Read More
  • Zydus Lifesciences gets NoC for generic Mesalamine suppositories 1000 mg
    27th Oct 2025, 14:08 PM

    Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis

    Read More
  • Zydus Lifesciences’ arm acquires balance share capital in Amplitude Surgical SA
    27th Oct 2025, 10:12 AM

    In view of the same, Zydus MedTech France now holds 100% share capital and voting rights of the Target Entity

    Read More
  • Zydus Lifesciences’ arm recalls over 1,500 boxes of antiviral medication
    13th Oct 2025, 11:30 AM

    The company has initiated the Class II nationwide recall on September 24

    Read More
  • Zydus Lifesciences gets NoC for generic Liothyronine tablets 5 mcg, 25 mcg
    7th Oct 2025, 10:23 AM

    Liothyronine tablets, a synthetic form of the thyroid hormone T3 (triiodothyronine), are primarily indicated for treating hypothyroidism

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Deflazacort oral suspension
    6th Oct 2025, 17:24 PM

    Deflazacort belongs to a group of medications called steroids

    Read More
  • Zydus Lifesciences gets EIR for oncology injectable manufacturing facility in Ahmedabad
    22nd Sep 2025, 10:32 AM

    The EIR has classified the facility as VAI

    Read More
  • Zydus Lifesciences’ arm launches first veterinary approved generic of Furosemide Tablets
    16th Sep 2025, 11:39 AM

    Manufactured under stringent quality standards, ZyVet’s Furosemide tablets are available in multiple strengths to accommodate patient-specific dosing

    Read More
  • Zydus Lifesciences’ arm launches generic of phenylpropanolamine hydrochloride tablets
    16th Sep 2025, 10:12 AM

    Phenylpropanolamine hydrochloride is commonly prescribed to treat urinary incontinence in dogs due to urethral sphincter hypotonus

    Read More
  • USFDA completes inspection at Zydus group’s injectable plant in Gujarat
    6th Sep 2025, 14:21 PM

    The inspection was conducted from August 25 to September 5, 2025 and concluded with 4 observations

    Read More
  • Zydus Lifesciences’ arm inks licensing, supply agreement with Synthon BV
    4th Sep 2025, 16:41 PM

    Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with Synthon BV of the Netherlands for Ozanimod Capsules for the United States market

    Read More
  • Zydus Lifesciences launches VaxiFlu in India
    2nd Sep 2025, 15:21 PM

    Vaxiflu - Trivalent Influenza Vaccine is recommended for individuals aged 6 months and above

    Read More
  • Zydus Lifesciences’ arm reports positive topline results from EPICS-III Phase 2(b)/3 clinical trial of Saroglitazar
    29th Aug 2025, 15:19 PM

    The company also planning to move forward with a regulatory submission to the U.S. Food and Drug Administration in the first quarter of 2026

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.